Trevena to Present at Three Upcoming Investor Events in March

Download as PDF

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be presenting at the Cowen 36th Annual Health Care Conference in Boston, the 28th Annual ROTH Conference in Orange County, and the Barclays Global Healthcare Conference in Miami. Details of the conferences are as follows:

Cowen 36th Annual Health Care Conference
Date: Wednesday, March 9
Location: Boston, MA
Presentation Time: 10:00 am ET, 7:00 am PT

28th Annual ROTH Conference
Date: Monday, March 14
Location: Orange County, CA
Presentation Time: 1:00 pm ET, 10:00 am PT

Barclays Global Healthcare Conference
Date: Wednesday, March 16
Location: Miami, FL
Presentation Time: 3:20 pm ET, 12:20 pm PT

All three presentations will be webcast live, and can be accessed through the “Investors” section of the Company's website at www.trevenainc.com. Following the conclusion of the presentations, each webcast will be archived and available for replay for 30 days.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified four biased ligand product candidates – oliceridine (TRV130) to treat moderate to severe acute pain intravenously (Phase 3), TRV027 to treat acute heart failure (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for acute episodic migraine and other CNS disorders (preclinical).

Trevena, Inc.
Jonathan Violin, Ph.D., 610-354-8840 x231
Sr. Director, Investor Relations
jviolin@trevenainc.com

Source: Trevena, Inc.

Released March 3, 2016